CenExel Clinical acquires New Jersey's AMRI

CenExel Clinical Research Inc., a clinical trial research company in Salt Lake City, has acquired Advanced Memory Research Institute (AMRI), the largest Alzheimer’s disease clinical research site in the Northeast. Based in Toms River, New Jersey, AMRI conducts Phase I through Phase IV studies, primarily in Alzheimer’s disease, memory loss and dementia research. The company will be known as CenExel AMRI.

“This acquisition further bolsters CenExel’s experience in CNS (central nervous system) trials, complementing the other nine centers in the CenExel network with strong backgrounds in this therapeutic area,” a CenExel statement said. “CenExel AMRI is led by Dr. Sanjiv K. Sharma, who has over 20 years of experience caring for patients with memory challenges.” The CenExel now operates 11 clinical research sites in the U.S., with specialties in neurology, pain, psychiatry, vaccines, dermatology/immunology, ethnic-bridging, sleep studies and clinical pharmacology.